A Comparison of Prophylactic Efficacy of Intravesical Instillation with Bacillus Calmette-Guerin and Thiotepa in Superficial Bladder Cancer.
- Author:
Soon Man PARK
1
;
Kwang Sung PARK
;
Yang Il PARK
Author Information
1. Department of Urology, Chonnam University, Medical School, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Intravesical therapy;
Superficial bladder tumor;
BCG;
Thiotepa
- MeSH:
Administration, Intravesical*;
Bacillus*;
Fever;
Follow-Up Studies;
Humans;
Mycobacterium bovis;
Recurrence;
Thiotepa*;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urology
1994;35(12):1333-1338
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We compared the prophylactic efficacy of intravesical BCG with thiotepa instillation after complete removal of superficial bladder cancer. Forty patients received BCG and 32 received thiotepa. The mean followup period was 29 months in BCG group, and 34 months in thiotepa group. The overall recurrence rate was 35% in BCG group compared with 53% in thiotepa group, showing difference statistically(p<0.05) The mean time to recurrence was 8.7 months in BCG group, and 7.2 months in thiotepa group(p>0.05). The overall recurrence index per 100 patient-months was also lower for the BCG versus the thiotepa group(1.21 versus 1.56, p>0.05). One patient in the BCG group and 4 in the thiotepa group had recurrent tumors with progression in stage. Side effects were irritative voiding symptoms(100%), fever and chills(10%), and inguinal lymphadenitis(2.5%) in BCG group, while irritative voiding symptoms(25%), fever and chills(6.3%), and myelosuppression (6.3%) in thiotepa group. Our results suggest that BCG is significantly superior to thiotepa in reducing bladder tumor recurrence and in retarding tumor progression.
